GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
高配当
同社は高配当銘柄であり、最新の配当性向は96.66%です。
安定配当
同社は過去5年間にわたり継続的に配当を実施しており、最新の配当性向は96.66%です。
適正水準
同社の最新のPEは13.82で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は388.63M株で、前四半期比で2.92%減少しています。
リチャード・ピゼナが保有
スター投資家リチャード・ピゼナは本銘柄を8.72K株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は-0.27です。